Related Experiment Video
Updated: Mar 28, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Dendritic cells in melanoma - immunohistochemical study and research trends
Roxana Ioana Nedelcu1, Daniela Adriana Ion, Cosmin Adrian Holeab
1Department of Pathophysiology II, Clinical Department No. 2, "Carol Davila" University of Medicine and Pharmacy, "Matei Bals" National Institute of Infectious Diseases - HIV÷AIDS and Infectious Diseases Academy, Bucharest, Romania; roxanaioana.nedelcu@yahoo.com.
Insights
Cutaneous dendritic cells are more frequent in regressed melanoma areas, suggesting their involvement in the regression phenomenon. Further research on dendritic cells in melanoma could lead to new therapeutic strategies.
Area of Science:
- Immunology
- Dermatology
- Oncology
Background:
- Cutaneous dendritic cells have diverse physiological and pathophysiological roles.
- The specific role of dendritic cells in melanoma regression remains unclear.
- Existing research on dendritic cells and melanoma requires further investigation.
Purpose of the Study:
- To analyze the current research landscape of dendritic cells in melanoma using scientometric analysis.
- To investigate the frequency and distribution of dendritic cells in melanoma with and without regression using immunohistochemistry.
Main Methods:
- Conducted a scientometric analysis of dendritic cells and melanoma research.
- Performed immunohistochemical analysis using CD1a and langerin markers.
- Evaluated dendritic cell frequency and distribution in regressed versus non-regressed melanoma areas.
Main Results:
- Dendritic cells were found to be more frequent in areas of melanoma regression compared to non-regressed areas.
- In regressed areas, dendritic cells predominantly showed a nodular pattern.
- In melanoma without regression, a diffuse pattern of dendritic cell distribution was most common.
Conclusions:
- Significant differences in dendritic cell frequency and distribution exist between regressed and non-regressed melanoma.
- These findings suggest a role for dendritic cells in the melanoma regression phenomenon.
- Further study of dendritic cells in melanoma regression may inform prognostic understanding and therapeutic development.
Abstract:
Cutaneous dendritic cells play multiple physiological roles and are involved in various pathophysiological processes. Research studies of dendritic cells abound in the medical literature. Nevertheless, the role of dendritic cells in melanoma regression phenomenon is not completely understood. We conducted a scientometric analysis in order to highlight the current state on research regarding dendritic cells and melanoma. We also performed an immunohistochemical study, using specific markers for dendritic cells (CD1a, langerin). We evaluated the frequency and distribution of dendritic cells in areas of tumor regression compared to the areas of inflammatory infiltrate of melanoma without regression. The immunohistochemical study we performed revealed that dendritic cells are more frequent in the regressed areas, comparing with non-regressed ones. In regressed areas, dendritic cells have a predominant nodular pattern (19 cases), followed by diffuse isolate pattern (eight cases) and mixed pattern (diffuse and nodular) (three cases). In melanoma without regression, most cases presented a diffuse pattern (27 cases) of dendritic cells distribution. In conclusion, our immunohistochemical study stressed differences between frequency and distribution of dendritic cells located in the melanoma with regression and melanoma without regression. These data suggest that dendritic cells are involved in the regression phenomenon. Following the literature analysis we obtained, we observed that dendritic cells profile in melanoma with regression was poorly studied. Insights into antitumor immune response and dendritic cells may be essential for the understanding of the potential prognostic role of dendritic cells in melanoma and for the development of new promising therapeutic strategies for melanoma.
